Pusic, Iskra <br/><br/>
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.  [electronic resource] 

 -  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation  Oct 2015 
 - 1761-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1523-6536 
<br/><br/><label>Standard No.: </label>10.1016/j.bbmt.2015.05.026  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Allografts<br/>Antimetabolites, Antineoplastic--adverse effects<br/>Azacitidine--adverse effects<br/>Combined Modality Therapy<br/>Decitabine<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Female<br/>Gastrointestinal Diseases--chemically induced<br/>Graft vs Host Disease--etiology<br/>Hematologic Diseases--chemically induced<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Infusions, Intravenous<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Maintenance Chemotherapy--methods<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Myelodysplastic Syndromes--drug therapy<br/>Prospective Studies<br/>Young Adult